Follow us on Instagram

JDDONLINE

 

September 12 - 13, 2020

NEW YORK, NY

January 15 -18, 2021

Orlando, FL

GIVE US YOUR THOUGHTS

Take the JDD Online Survey

1
1

CURRENT ISSUE HIGHLIGHTS

CME/CE: ABOUT FACE: Navigating Neuromodulators and Injection Techniques for Optimal Results

Published online March 31, 2020

Botulinum Neurotoxin Type A Composition Four BTXA products are commercially available in the United States with approval for cosmeti...

read more
CME: Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update

Published online March 20, 2020

Selective weakening of the muscles of facial expression with BoNT-A has been found to improve the appearance of the overlying rhytides ...

read more
Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients

Published online April 2, 2020

The high cost of prescription medications continues to be a challenge for patients and prescribers in dermatology. Strategies to contro...

read more
Risk of Non-Melanoma Skin Cancer in Connective Tissue Disease and The Impact of Immunosuppressive Therapy

Published online April 3, 2020

Connective tissue diseases (CTD), specifically systemic lupus erythematosus (SLE), scleroderma and Sjogren’s disease have been report...

read more
Analysis of Wait Times for Online Dermatology Appointments in Most and Least Dermatologist-Dense Cities

Published online April 3, 2020

In the United States (US), there have been long wait times for new patient appointments and unequal geographic distribution of dermatologists. 1,2 W...

read more
Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

Published online March 27, 2020

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation cal...

read more
Erratum

Published online April 1, 2020

Due to a production error, Table 1 in the CME supplement, Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Pan...

read more
Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol

Published online March 27, 2020

Psoriasis is a chronic, immune-mediated disease with prevalence estimates within adult populations ranging from 0.91% in the USA to 8.5...

read more
Is It Time to Redefine Lidocaine Administration Guidelines in Mohs Surgery?

Published online March 20, 2020

Current FDA guidelines for lidocaine use in Mohs micrographic surgery (MMS) do not account for the lengthy duration of MMS, which is on average 2-4 h...

read more
Erratum

Published online March 27, 2020

RE: Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine by Charles W. Lynde MD FRCPC, Gordon Sussman MD FRCPC...

read more

Blog

Special Features: Global Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Global Pandemic: A Statement from the JDD

The global COVID-19 pandemic has greatly impacted our lives: how we gather and connect has changed to ensure the health and safety of our communities. During this time, as researchers, health professionals, and scientists around the world collaborate to develop solutions to protect our global community, the JDD has committed to continuing to publish the latest research, updates, and information to help providers better serve patients.

Medical Bioethics in Dermatologic Procedures

The US Food and Drug Administration (FDA) held a hearing on the safety of dermal fillers in November of 2008 which generated a great deal of media attention and, more importantly, got our attention. The adverse reporting data came from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database and numbered 930 cases over the past 6 years, bringing the complication rate to an estimated 1 in 10 000. Some of the complications were severe, such as facial palsy or anaphylaxis; while others included scarring. Such rare but grave complications are generally considered acceptable risks for treatments of medical illnesses (eg, infections or carcinomas); but are these rare complications for elective cosmetic enhancement acceptable?

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

| Featured Articles, Global Health | No Comments
While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.…

Current Issue Highlights

| JDD Highlights | No Comments
New Dermatological Research is available now- view this months' JDD features, case reports, and research below: Dermatologists respond regarding the impact of COVID-19 and examine the potential impact of drugs…

What Women Don’t Want … Psoriasis

| Podcast Highlights | No Comments
In this edition of the JDD Podcast, Dr. Adam Friedman is joined by Dr. Deirdre Hooper, Associate Clinical Professor in the Department of Dermatology at both Louisiana State University and…

GW Announces Virtual Learning Opportunity

| Derm Community, Education, Global Health | No Comments
DC Academy of Dermatology   Monday, March 23, 2020 - 8:30am Register Contact: Kayleigh Hausmann The George Washington University School of Medical and Health Sciences has announced it will host…